Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy

Parkinson's disease is the second most common neurodegenerative pathology. Due to the limitations of existing therapeutic approaches, novel anti-parkinsonian medicines with non-dopamine mechanisms of action are clearly needed. One of the promising pharmacological targets for anti-Parkinson drug...

Full description

Saved in:

Bibliographic Details
Published in:	Biomolecules (Basel, Switzerland) Vol. 13; no. 1; p. 9
Main Authors:	Sukhanov, Ilya, Dorotenko, Artem, Fesenko, Zoia, Savchenko, Artem, Efimova, Evgeniya V, Mor, Mikael S, Belozertseva, Irina V, Sotnikova, Tatyana D, Gainetdinov, Raul R
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 21-12-2022 MDPI
Subjects:	Alzheimer's disease Animals Basal ganglia Boxes Carbidopa Catalepsy Catalepsy - complications Catalepsy - drug therapy Central nervous system diseases Design of experiments Dopamine Dopamine transporter dopamine transporter knockout rat Drug development Drug dosages hypodopaminergia Levodopa Levodopa - pharmacology Levodopa - therapeutic use Locomotor activity Movement disorders Neurodegenerative diseases Parkinson Disease - drug therapy Parkinson Disease - etiology Parkinson's disease PDE10A inhibitors Rats Tyrosine 3-monooxygenase St Petersburg Russia Russia hypodopaminergia locomotor activity PDE10A inhibitors Parkinson’s disease dopamine transporter knockout rat
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!